Digital therapy for prenatal insomnia may prevent postpartum depression

By Jess Berthold
 

Pregnant woman on couch

About 38 percent of women experience insomnia during pregnancy, which in turn is associated with a 30 percent increased risk of pre-term birth.

A digital version of cognitive behavioral therapy, or dCBT, that previously had been shown to reduce insomnia during pregnancy may also prevent postpartum depression and reduce insomnia and anxiety in women up to six months after they give birth, according to a new study by researchers at UC San Francisco.

The study, which appears in the current issue of the journal Sleep, is unique in showing that non-depressed women who received dCBT for insomnia during pregnancy also slept better and had less depression several months into the postpartum period. The study is a follow-up to research that appeared January 2020 in JAMA Psychiatry showing the treatment reduced insomnia, depression, and anxiety symptoms during pregnancy.

“We were curious to see whether the benefits of dCBT for insomnia would maintain after the birth of the child, especially given the demands of having a young infant,” said Jennifer Felder, PhD, an assistant adjunct professor in the UCSF Department of Psychiatry and Behavioral Sciences and core research faculty member at the UCSF Osher Center for Integrative Health, who led the study. “We were particularly excited to see the benefits lasted to six months not just for insomnia, but for mental health more broadly.”

Insomnia in pregnancy is common, yet understudied

About 38 percent of women experience insomnia during pregnancy, which in turn is associated with a 30 percent increased risk of pre-term birth. Yet there has not been a great deal of research on whether sleep interventions are effective for pregnant women.

Studies on how to prevent postpartum depression, which affects up to 15 percent of women, have focused on women with a history of depression or sub-clinical depression symptoms. No research has studied whether treating insomnia may prevent postpartum depression.

“I’ve heard patients say, over and over, that their postpartum mental health began to suffer when their insomnia started, suggesting there is a link,” Felder said. “We know that postpartum can be a vulnerable time for becoming depressed, and it is possible that this intervention may prevent that.”

The current study involved 208 participants, 105 of whom were randomized to the dCBT treatment—a self-paced sleep app called Sleepio that patients used for 20 minutes at a time for up to six sessions. At three months postpartum, 4 percent of women who used the app were rated as likely depressed, compared to 18 percent of the women who got usual care.

Digital therapy: More affordable, more scalable

Usual care included medication or general sleep hygiene tips from physicians and others. dCBT may work better because it’s more individualized and addresses the factors known to perpetuate insomnia, Felder said.

“Participants can set their own goals, and their treatment recommendations are tailored based on what their previous week’s sleep looked like,” Felder said. “The magic of the treatment is what happens between sessions, the tactics the participants put into practice, such as keeping a sleep diary, stabilizing their wake time, spending less time in bed tossing and turning, and prioritizing an adequate wind down before bed.”

Given the shortage of mental health clinicians who are trained to deliver cognitive behavioral therapy, it’s important to test treatments that women can actually access, Felder added: “This is a scalable intervention with a low risk profile—and it works.”

Felder said she and her colleagues plan to conduct a large-scale study in the near future to determine conclusively whether dCBT for insomnia prevents postpartum depression. Additionally, she is currently piloting a mindfulness-based intervention to help pregnant people cope with sleep disturbances caused by discomfort, pain, or an active mind.

Co-Authors: Other authors are Elissa Epel, PhD; Andrew Krystal, MD, MS; and Aric Prather, PhD, from the UCSF Department of Psychiatry and Behavioral Sciences; and John Neuhaus, PhD, from the UCSF Department of Epidemiology and Biostatistics.

Funding: The study was supported by the UCSF California Preterm Birth Initiative transdisciplinary postdoctoral fellowship, funded by Marc and Lynne Benioff, and the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number UL1 TR001872.

Disclosures: Krystal consults with multiple health technology and pharmaceutical companies, including Big Health, which produces Sleepio. His involvement in the current study was in manuscript preparation.

The Sleepio app is a for-profit app with an annual subscription of approximately $530, which is covered by some health plans and large employers. Other dCBTi apps available for insomnia include Somryst and CBT-i Coach.

Read the journal article

Related articles


About UCSF Psychiatry and Behavioral Sciences

The UCSF Department of Psychiatry and Behavioral Sciences and the Langley Porter Psychiatric Institute are among the nation's foremost resources in the fields of child, adolescent, adult, and geriatric mental health. Together they constitute one of the largest departments in the UCSF School of Medicine and the UCSF Weill Institute for Neurosciences, with a mission focused on research (basic, translational, clinical), teaching, patient care, and public service.

UCSF Psychiatry and Behavioral Sciences conducts its clinical, educational, and research efforts at a variety of locations in Northern California, including Langley Porter Psychiatric Hospital and Clinics; UCSF Medical Centers at Parnassus Heights, Mission Bay, and Mount Zion; UCSF Benioff Children’s Hospitals in San Francisco and Oakland; Zuckerberg San Francisco General Hospital and Trauma Center; the San Francisco VA Health Care System; UCSF Fresno; and numerous community-based sites around the San Francisco Bay Area.

About the UCSF Weill Institute for Neurosciences

The UCSF Weill Institute for Neurosciences, established by the extraordinary generosity of Joan and Sanford I. "Sandy" Weill, brings together world-class researchers with top-ranked physicians to solve some of the most complex challenges in the human brain.

The UCSF Weill Institute leverages UCSF’s unrivaled bench-to-bedside excellence in the neurosciences. It unites three UCSF departments—Psychiatry and Behavioral Sciences, Neurology, and Neurological Surgery—that are highly esteemed for both patient care and research, as well as the Neuroscience Graduate Program, a cross-disciplinary alliance of nearly 100 UCSF faculty members from 15 basic-science departments, as well as the UCSF Institute for Neurodegenerative Diseases, a multidisciplinary research center focused on finding effective treatments for Alzheimer’s disease, frontotemporal dementia, Parkinson’s disease, and other neurodegenerative disorders.

About UCSF

The University of California, San Francisco (UCSF) is exclusively focused on the health sciences and is dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. UCSF Health, which serves as UCSF’s primary academic medical center, includes top-ranked specialty hospitals and other clinical programs, and has affiliations throughout the Bay Area.